Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2026-05-04

No results posted yet for this study

Summary

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect of chemoradiation that can cause pain and difficulty swallowing. Usual management of these side effects typically consists of using mouth rinses and pain medications during treatment and for several weeks after completion of treatment. BMX-001 neutralizes harmful substances in the body, preventing damage to macromolecules such as DNA and minimizes free radical-related toxicity in normal tissues. Adding BMX-001 to usual symptom management may be more effective than usual symptom management alone at reducing oral mucositis in patients receiving chemoradiation for head and neck cancer.

Conditions

  • Stage I Laryngeal Cancer AJCC v8
  • Stage I Lip and Oral Cavity Cancer AJCC v8
  • Stage I Nasopharyngeal Carcinoma AJCC v8
  • Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Head and Neck Squamous Cell Carcinoma
  • Hypopharyngeal Squamous Cell Carcinoma
  • Laryngeal Squamous Cell Carcinoma
  • Nasopharyngeal Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma
  • Oropharyngeal Squamous Cell Carcinoma
  • Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage 0 Hypopharyngeal Carcinoma AJCC v8
  • Stage 0 Nasopharyngeal Carcinoma AJCC v8
  • Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage I Hypopharyngeal Carcinoma AJCC v8
  • Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage II Hypopharyngeal Carcinoma AJCC v8
  • Stage II Laryngeal Cancer AJCC v8
  • Stage II Lip and Oral Cavity Cancer AJCC v8
  • Stage II Nasopharyngeal Carcinoma AJCC v8
  • Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage III Hypopharyngeal Carcinoma AJCC v8
  • Stage III Laryngeal Cancer AJCC v8
  • Stage III Lip and Oral Cavity Cancer AJCC v8
  • Stage III Nasopharyngeal Carcinoma AJCC v8
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IVA Hypopharyngeal Carcinoma AJCC v8
  • Stage IVA Laryngeal Cancer AJCC v8
  • Stage IVA Lip and Oral Cavity Cancer AJCC v8
  • Stage IVA Nasopharyngeal Carcinoma AJCC v8
  • Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IVB Hypopharyngeal Carcinoma AJCC v8
  • Stage IVB Laryngeal Cancer AJCC v8
  • Stage IVB Lip and Oral Cavity Cancer AJCC v8
  • Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stomatitis

Interventions

RADIATION

Image Guided Radiation Therapy

Undergo image-guided radiation therapy

RADIATION

Intensity-Modulated Radiation Therapy

Undergo intensity-modulated radiation therapy

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

MnSOD Mimetic BMX-001

Given SC

DRUG

Placebo Administration

Given SC

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Best Practice

Receive usual symptom management

PROCEDURE

Biospecimen Collection

Undergo collection of blood, serum, and/or plasma samples

DRUG

Cisplatin

Given cisplatin

PROCEDURE

Computed Tomography

Undergo CT

Sponsors & Collaborators

Principal Investigators

  • David M Brizel · NRG Oncology

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-23
Primary Completion
2027-01-01
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06532279 on ClinicalTrials.gov